Continuous low dose subcutaneous lidocaine for treatment of pneumonia in COVID*19 patients.   A randomised controlled (RCT) open*label phase III study.

Phase 3

Withdrawn

• Conditions: corona virus; COVID-19; 10024970

• Registration Number: NL-OMON49706
• Lead Sponsor: Stichting Dutch Covid19 Lidocaine ARDS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

1. Age *18 years. 
2. Acute disease with radiographic*
confirmed pneumonia with a positive test for COVID*19.
3.Patients admitted to the hospital ward with spontaneous breathing are eligible
 for inclusion in the study.

Exclusion Criteria

1.
Patients known with allergy or hypersensitivity to lidocaine, xylocaine or ligno
caine.  
2. Treatment with Ivermectin. Reportedly, Ivermectin inhibits the in*
vitro replication of SARS*1 CoV*2.
3. Treatment with methylprednisolone as sepsis therapy. 

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The disappearance of the main symptoms of the COVID*19*<br /><br>induced pneumonia within 5 days after the initiation of the <br /><br>continuous low dose subcutaneous infusion of lidocaine in 50% of the patients. T<br /><br>he relief of these symptoms must be  maintained for at least 48 hours.  </p><br>